EWM
OREX

Edge Wealth Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Edge Wealth Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-150
Closed -$3K – 518
2015
Q4 		$3K Hold
150
– – ﹤0.01% 383
2015
Q3 		$3K Hold
150
– – ﹤0.01% 386
2015
Q2 		$7K Sell
150
-50
-25% -$2.99K ﹤0.01% 326
2015
Q1 		$16K Buy
+200
New +$12.4K 0.01% 271
2014
Q4 		– Sell
-700
Closed -$30K – 466
2014
Q3 		$30K Buy
700
+500
+250% +$26.9K 0.01% 232
2014
Q2 		$12K Buy
+200
New +$11.6K 0.01% 282

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Edge Wealth Management's OREX Position: Q1 2016 in Review

Edge Wealth Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 150 shares — an estimated $3K sold.

Edge Wealth Management first reported a position in OREX in Q2 2014 and held it in 6 quarters. The position peaked at $30K in Q3 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Edge Wealth Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Edge Wealth Management sold 150 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $3K.
  • Edge Wealth Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 6 quarters.
  • Edge Wealth Management's Orexigen Therapeutics, Inc. position peaked at $30K in Q3 2014.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Edge Wealth Management's 13F filing for Q1 2016, filed 8 Apr 2016.